Value of post-therapy 177Lu-PSMA images for accurate interpretation of therapy response with 68Ga-PSMA PET/CT

M. Tuncel; T. Telli

doi:10.1016/j.remn.2017.05.004

Value of post-therapy ¹⁷⁷Lu-PSMA images for accurate interpretation of therapy response with ⁶⁸Ga-PSMA PET/CT

M. Tuncel
, T. Telli

Nükleer Tıp Anabilim Dalı

Hacettepe University

Araştırma sonucu: Dergiye katkı › Makale › bilirkişi

2 Alıntılar (Scopus)

Özet

A 54-year-old man with progressive prostate cancer underwent a ⁶⁸Ga-PSMA PET/CT, which showed lymph node and bone metastases. After 2-cycles of ¹⁷⁷Lu-PSMA therapy, the repeated ⁶⁸Ga-PSMA PET/CT showed decreased radiotracer uptake in lymph node and bones metastases, but there were new lesions which may be compatible with progression or tumour sink-effect. A review of ¹⁷⁷Lu-PSMA-therapy images revealed that new lesions in the second PET/CT were the metastatic lesions that progressed after the first PET/CT, and subsequently showed a good response. The patient received additional cycles of ¹⁷⁷Lu-PSMA therapy, and the disease regressed further, with a PSA of 0.06 ng/ml. Response evaluation of new therapeutic diagnostics (theranostic) agents needs a review of not only diagnostic PET/CT images, but also post-therapy images and laboratory results.

Orijinal dil	İngilizce
Sayfa (başlangıç-bitiş)	114-117
Sayfa sayısı	4
Dergi	Revista Espanola de Medicina Nuclear e Imagen Molecular
Hacim	37
Basın numarası	2
DOI'lar	https://doi.org/10.1016/j.remn.2017.05.004
Yayın durumu	Yayınlandı - 1 Mar 2018

BM SKH

Bu sonuç, aşağıdaki Sürdürülebilir Kalkınma Hedefine/Hedeflerine katkıda bulunur

SKH 3 Sağlık ve Kaliteli Yaşam

Belgeye Erişim

10.1016/j.remn.2017.05.004

Diger dosyalar ve linkler

Link to publication in Scopus

Bundan alıntı yap

@article{f434e955a7864ded96543cf8ba20f56a,

title = "Value of post-therapy 177Lu-PSMA images for accurate interpretation of therapy response with 68Ga-PSMA PET/CT",

abstract = "A 54-year-old man with progressive prostate cancer underwent a 68Ga-PSMA PET/CT, which showed lymph node and bone metastases. After 2-cycles of 177Lu-PSMA therapy, the repeated 68Ga-PSMA PET/CT showed decreased radiotracer uptake in lymph node and bones metastases, but there were new lesions which may be compatible with progression or tumour sink-effect. A review of 177Lu-PSMA-therapy images revealed that new lesions in the second PET/CT were the metastatic lesions that progressed after the first PET/CT, and subsequently showed a good response. The patient received additional cycles of 177Lu-PSMA therapy, and the disease regressed further, with a PSA of 0.06 ng/ml. Response evaluation of new therapeutic diagnostics (theranostic) agents needs a review of not only diagnostic PET/CT images, but also post-therapy images and laboratory results.",

keywords = "Ga-PSMA, Lu- PSMA, Therapeutic response, Tumor sink effect",

author = "M. Tuncel and T. Telli",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Espa{\~n}a, S.L.U. y SEMNIM",

year = "2018",

month = mar,

day = "1",

doi = "10.1016/j.remn.2017.05.004",

language = "English",

volume = "37",

pages = "114--117",

journal = "Revista Espanola de Medicina Nuclear e Imagen Molecular",

issn = "2253-654X",

publisher = "Ediciones Doyma, S.L.",

number = "2",

}

TY - JOUR

T1 - Value of post-therapy 177Lu-PSMA images for accurate interpretation of therapy response with 68Ga-PSMA PET/CT

AU - Tuncel, M.

AU - Telli, T.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - A 54-year-old man with progressive prostate cancer underwent a 68Ga-PSMA PET/CT, which showed lymph node and bone metastases. After 2-cycles of 177Lu-PSMA therapy, the repeated 68Ga-PSMA PET/CT showed decreased radiotracer uptake in lymph node and bones metastases, but there were new lesions which may be compatible with progression or tumour sink-effect. A review of 177Lu-PSMA-therapy images revealed that new lesions in the second PET/CT were the metastatic lesions that progressed after the first PET/CT, and subsequently showed a good response. The patient received additional cycles of 177Lu-PSMA therapy, and the disease regressed further, with a PSA of 0.06 ng/ml. Response evaluation of new therapeutic diagnostics (theranostic) agents needs a review of not only diagnostic PET/CT images, but also post-therapy images and laboratory results.

AB - A 54-year-old man with progressive prostate cancer underwent a 68Ga-PSMA PET/CT, which showed lymph node and bone metastases. After 2-cycles of 177Lu-PSMA therapy, the repeated 68Ga-PSMA PET/CT showed decreased radiotracer uptake in lymph node and bones metastases, but there were new lesions which may be compatible with progression or tumour sink-effect. A review of 177Lu-PSMA-therapy images revealed that new lesions in the second PET/CT were the metastatic lesions that progressed after the first PET/CT, and subsequently showed a good response. The patient received additional cycles of 177Lu-PSMA therapy, and the disease regressed further, with a PSA of 0.06 ng/ml. Response evaluation of new therapeutic diagnostics (theranostic) agents needs a review of not only diagnostic PET/CT images, but also post-therapy images and laboratory results.

KW - Ga-PSMA

KW - Lu- PSMA

KW - Therapeutic response

KW - Tumor sink effect

UR - https://www.scopus.com/pages/publications/85025468907

U2 - 10.1016/j.remn.2017.05.004

DO - 10.1016/j.remn.2017.05.004

M3 - Article

C2 - 28750750

AN - SCOPUS:85025468907

SN - 2253-654X

VL - 37

SP - 114

EP - 117

JO - Revista Espanola de Medicina Nuclear e Imagen Molecular

JF - Revista Espanola de Medicina Nuclear e Imagen Molecular

IS - 2

ER -